APA

Bowles J. A., Wang S., Link B. K., Allan B., Beuerlein G., Campbell M., Marquis D., Ondek B., Wooldridge J. E., Smith B. J., Breitmeyer J. B. & Weiner G. J. (20061102). Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. : Blood.

Chicago

Bowles Julie A, Wang Siao-Yi, Link Brian K, Allan Barrett, Beuerlein Gregory, Campbell Mary-Ann, Marquis David, Ondek Brian, Wooldridge James E, Smith Brian J, Breitmeyer James B and Weiner George J. 20061102. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. : Blood.

Harvard

Bowles J. A., Wang S., Link B. K., Allan B., Beuerlein G., Campbell M., Marquis D., Ondek B., Wooldridge J. E., Smith B. J., Breitmeyer J. B. and Weiner G. J. (20061102). Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. : Blood.

MLA

Bowles Julie A, Wang Siao-Yi, Link Brian K, Allan Barrett, Beuerlein Gregory, Campbell Mary-Ann, Marquis David, Ondek Brian, Wooldridge James E, Smith Brian J, Breitmeyer James B and Weiner George J. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. : Blood. 20061102.